Case Report: Anterior Scleritis Presenting as a Primary Ocular Manifestation in Multisystem Inflammatory Syndrome in Children With COVID-19

Daisuke Matsubara*, Daisuke Tamura¹, Yuka Kasuya², Yoshitaka Mizobe¹, Mami Hiwada¹, Mitsuru Seki¹, Shinji Makino² and Takanori Yamagata¹

¹Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan, ²Department of Ophthalmology, Jichi Medical University, Shimotsuke, Japan

CASE DESCRIPTION

A previously healthy 11-year-old Japanese boy was diagnosed with COVID-19 by nasopharyngeal polymerase chain reaction testing, attended with his parents. At the time, the delta variant was prevalent in Japan. The patient's only symptom was mild fever for 2 days. Five weeks later (day 1),...
he experienced bilateral eye pain that disturbed his sleep, and photophobia. On day 5, he developed a fever of 38.5°C, bilateral red eyes, and general malaise, followed by abdominal pain, frequent vomiting, and watery diarrhea on day 6. During this period, he visited an ophthalmology clinic several times, and was diagnosed with severe anterior scleritis and conjunctivitis of unknown origin based on the slit-lamp examination; the examination showed microvascular dilatation in various layers, including not only in the conjunctiva, but also in the episclera and deep sclera. Topical steroids (0.1% fluorometholone) did not improve the ocular symptoms. Subsequently, the patient presented with a high fever of 40°C and his general condition deteriorated, which led to his admission in our hospital on day 10. His vital signs were stable, with a body temperature of 37.7°C, respiratory rate of 16/min, heart rate of 117/min, blood pressure of 121/70 mmHg, and SpO2 of 98% on ambient air. Physical examination revealed cervical lymphadenopathy, abdominal tenderness, hypoacloric bowel sounds, and rashes (dime-size annular plaques) on the inner thigh. Ophthalmological examination revealed anterior scleritis suggested by diffuse episcleral and deep scleral injection with microvascular dilatation, as well as bilateral conjunctivitis (Figures 1A,B). He did not show any discharges or matting of eyelashes. No uveitis, vitritis, or retinitis was observed. The visual acuity of the patient was normal. The fundal examination findings were unremarkable (Figure 2). Ocular ultrasonography was not performed. The film array showed no evidence of active viral infections, including those caused by SARS-CoV-2. Table 1 shows the laboratory findings. The patient presented a normal range of leukocytes with decreased lymphocyte count (600/µL), hyperinflammatory state (C-reactive protein of 10.5 mg/dL, procalcitonin of 0.86 ng/dL, serum amyloid A of 1,219 µg/mL, ferritin of 252 ng/dL, and lactase dehydrogenase of 495 U/L), hypercoagulopathy (FDP of 12.1 µg/mL and D-dimer of 3.8 µg/mL), and elevated markers of cardiac stress/damage (brain natriuretic peptide of 47 pg/mL, N-terminal pro-brain natriuretic peptide of 704 pg/mL, and troponin T of 0.02 ng/mL). The patient also showed liver dysfunction (alanine aminotransferase of 213 U/L and aspartate aminotransferase of 385 U/L), and dehydration with hyponatremia and hypoalbuminemia. Chest radiography and electrocardiography findings were unremarkable. Echocardiography demonstrated decreased cardiac function with a left ventricular ejection fraction (LVEF) of 48% (using a modified Simpson method). Although the patient showed some features compatible with KD, he was diagnosed as having MIS-C based on the definition by the Centers for Disease Control and Prevention and the World Health Organization (3, 4). Following intravenous immunoglobulin (2 g/kg) administration and heparinization on day 11, his fever subsided by the next day (day 12). Notably, the ocular manifestations improved dramatically after intravenous immunoglobulin administration; without additional topical steroids (Figures 1C,D). Serial echocardiography demonstrated gradual improvement in LVEF, and LVEF improved to normal by day 14. The patient's coronary arteries were normal. The patient was discharged on day 18 and had uneventful cardiac and ocular manifestations 6 months after discharge (Figure 3).

**DISCUSSION**

MIS-C is defined as an individual aged less than 21 years who presents fever, laboratory evidence of inflammation, multisystem organ involvement (at least in 2 organ systems, such as ocular, dermatologic, gastrointestinal, and cardiac manifestations) and laboratory confirmed SARS-CoV-2 infection or epidemiologic link to a person with COVID-19 (3, 4). Therefore, MIS-C can present with various clinical features. While the literature is limited regarding ocular reports associated with MIS-C, anterior uveitis has recently been reported in addition to conjunctivitis (5–9). The present case was unique for the following two reasons: 1) the patient showed severe ocular manifestations as the primary symptom of MIS-C prior to other findings, such as fever or gastrointestinal manifestations, which could lead to delay in diagnosis, and 2) he suffered anterior scleritis, an unusual and severe form of inflammatory...
eye disease, rather than conjunctivitis. In addition, his detailed ocular examination provided us with clinical clues regarding the possible pathogenesis of MIS-C compared with KD.

To our knowledge, this is the first report of severe ocular manifestation as the primary symptom of MIS-C. Recently, several reports have demonstrated symptomatic anterior uveitis in a subset of patients with MIS-C (5–9). Notably, ocular symptoms associated with uveitis, such as blurring of vision or photophobia, became apparent at the subacute stage of disease, during or after the treatment of other MIS-C-related organ dysfunctions, such as myocarditis. The present case is unique in that the patient's severe ocular manifestation preceded other symptoms, such as fever, which could result in a delay in the diagnosis of MIS-C. We therefore recommend that pediatricians and physicians should keep in mind that severe ocular manifestations could be the first symptom of MIS-C, and MIS-C should be considered for a differential diagnosis, especially in COVID-19-prevalent areas. The patient in the present case suffered from anterior scleritis as well as conjunctivitis. Ocular ultrasonography was not performed, and concurrent posterior scleritis was not fully ruled out. Since he first complained of bilateral eye pain and photophobia, followed by bilateral red eyes, scleritis could have preceded conjunctivitis. Scleritis is an inflammation in the episcleral and scleral tissues in both superficial and deep episcleral vessels, and can be vision-threatening. It is often associated with an underlying systemic disease (in up to 50% of patients), suggesting that the immune system may play a role in the pathogenesis of scleritis (10). To date, only one report has described bilateral anterior scleritis concomitant with anterior uveitis. In this report a 17-year-old boy with MIS-C complained of bilateral red eyes, eye pain, photophobia, and blurring of vision, with subsequent fever that occurred 1-week after post-admission, and after a 3-day course of intravenous methylprednisolone and tocilizumab administration (6). His eye condition required additional oral prednisolone and eye drops (0.1% dexamethasone) for up to a 6-week period. In contrast, in the MIS-C with scleritis case presented here, intravenous immunoglobulin was administered for MIS-C-related organ dysfunctions including

### TABLE 1 | Laboratory test at admission.

| [Blood cell count]                      | [Film array]      |
|----------------------------------------|-------------------|
| White blood cell 9,800 µL            | Viruses           |
| Neutrophil 85.7 % Adenovirus N/D     |                   |
| Lymphocyte 0.1 % Coronavirus 229E N/D |                   |
| Red blood cell 447 × 10⁴ µL          |                   |
| Hemoglobin 12.8 g/dL Coronavirus NL63 N/D |
| Platelets count 30.8 × 10⁴ µL        |                   |
| [Coagulation test]                    |                   |
| FDP 12.1 µg/mL                       |                   |
| Fibrinogen 739 mg/dL Human metapneumovirus N/D |
| D-dimer 3.8 µg/mL Human Rhinovirus/Enterovirus N/D |
| [Blood biochemistry]                 |                   |
| CRP 10.5 mg/dL                       |                   |
| Total Protein 7.6 g/dL               |                   |
| Albumin 3 g/dL                       |                   |
| BUN 24 mg/dL                         |                   |
| Creatinine 0.64 mg/dL                |                   |
| Creatinine kinase 67 U/L             |                   |
| AST 385 U/L                          |                   |
| ALT 213 U/L                          |                   |
| LDH 495 U/L                          |                   |
| Sodium 135 mmol/L                    |                   |
| Potassium 4 mmol/L                   |                   |
| Chloride 99 mmol/L                   |                   |
| Procaltocin 0.86 ng/dL               |                   |
| Ferritin 252 ng/dL                   |                   |
| Serum Amyloid A 1,219 µg/mL          |                   |
| NT-pBNP 704 pg/mL                    |                   |
| BNP 47 pg/mL                         |                   |
| Troponin T 0.02 ng/mL                |                   |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CRP, C-reactive protein; FDP, fibrinogen degradation products; LDH, lactase dehydrogenase; NT-pBNP, N-terminal pro-brain natriuretic peptide.
fever, gastrointestinal symptoms, myocardial dysfunction and ocular symptoms, as the patient had been refractory to a steroid eye drop before admission. Fortunately, intravenous immunoglobulin administration alone immediately relieved the patient's eye symptoms together with other symptoms. He showed no ongoing inflammation thereafter. The precise mechanism is unknown why the immunoglobulin was effective for scleritis in the present case with MIS-C, as therapeutic options usually include steroid and immunosuppressive drugs for non-infectious scleritis (10). However, it is reasonable to consider immunoglobulin administration as a first step therapeutic option if the patient with MIS-C show severe ocular manifestation refractory to a steroid eye drop. Moreover, a thorough ophthalmological examination should be performed to avoid misdiagnosing the potentially vision-threatening condition of scleritis/uveitis as common conjunctivitis.

To some extent MIS-C mimics KD, and 40% of MIS-C cases meet the criteria for either complete or incomplete KD (2). Compared with KD, MIS-C more often presents with gastrointestinal (92%) and cardiovascular (80%) symptoms, both of which were seen in the present case (2). Considering eye manifestations, both MIS-C and KD show similar ocular inflammation in the form of conjunctivitis and anterior uveitis (11, 12). The fundal findings in KD have not been fully examined in the currently available English literature, probably because of technical problems with examining infants/young children (usually younger than MIS-C patients). Posterior involvement in KD is rare and is usually limited to case reports (13). Similarly, fundus findings in MIS-C are scarce in the literature, but some reports have demonstrated normal findings, as described in this case (6, 7, 9).

Considering that both MIS-C and KD mainly involve the anterior segment of the eyes, we speculate that MIS-C and KD have a similar pathogenesis. To prove this hypothesis, more information using multimodalities, such as histopathological examinations, is required.

Coronary arterial abnormalities were unique findings in both MIS-C and KD groups. In patients with KD, they may determine the long-term morbidity and mortality in 20–25% of untreated cases; therefore, early diagnosis and treatment are essential to prevent cardiac complications (14). When examining the eyes for small vessel changes, we could predict the condition of the coronary arteries in patients with KD. Lim et al. (15) demonstrated a significant association between the diameter of coronary arteries and retinal arteriolar geometric changes in 11 children with new-onset of KD and with a median age of 5.9 years. Similarly, a subset of patients with MIS-C present with coronary complications, although the precise underlying mechanism is unclear. Our future studies will evaluate the vascular condition, including that of the coronary arteries, through the eyes using noninvasive techniques; this research could lead to a deeper understanding of the pathophysiology of MIS-C. The relatively older-age-onset of MIS-C compared to KD would be advantageous for such ophthalmologic examinations.

In conclusion, MIS-C presents with a wide variety of clinical manifestations, with the present case showing severe ocular manifestations in the form of anterior scleritis as the primary MIS-C symptom. In addition, ocular scleritis could be sight-threatening, and therefore it may require specific treatment in MIS-C cases such as intravenous immunoglobulin. Detailed ocular examinations by ophthalmologists could refine and guarantee the diagnosis of MIS-C, and could possibly help in further clarifying the MIS-C pathophysiology.
DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

DM, DT, YK, YM, MH, and MS managed the patient, contributed to the conception of the study, and drafted the manuscript. YK and SM reviewed the manuscript from the ophthalmological perspective. TY critically reviewed the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

We would like to thank Editage (www.editage.com) for English language editing.

REFERENCES

1. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuﬀreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. (2020) 395:1771–8. doi: 10.1016/S0140-6736(20)31103-X
2. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inﬂammatory syndrome in U.S. Children and adolescents. N Engl J Med. (2020) 383:334–46. doi: 10.1056/NEJMo2021680
3. CDC Health Alert Network. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease 2019 (COVID-19). Available online at: https://emergency.cdc.gov/han/2020/han00432.asp (accessed April 27, 2022).
4. World Health Organization Scientiﬁc Brief. Multisystem Inflammatory Syndrome in Children and Adolescents With COVID-19. Available online at: https://www.who.int/publications/i/item/multisystem-infl ammatory-syndrome-in-children-and-adolescents-with-covid-19 (accessed April 27, 2022).
5. Wong Chung JERE, Engin O, Wolfs TIFF, Renson TJC, de Boer JH. Anterior uveitis in paediatric inﬂammatory multisystem syndrome temporally associated with SARS-CoV-2. Lancet. (2021) 397:e10. doi: 10.1016/S0140-6736(21)00579-1
6. Islam M, Chou M, Braitwaite T, Siddiqui A. Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inﬂammatory multisystem syndrome temporally associated with COVID-19. Lancet Rheumatol. (2021) 3:e18. doi: 10.1016/S2665-9913(21)00272-1
7. Sim AYC, Naffi AA, Fai TS, Kori N, Zaadi WAW, Periyasamy P, et al. Bilateral intermediate uveitis in a healthy teenager with the multisystem inﬂammatory syndrome in children secondary to COVID-19 infection. J Med Virol. (2022) 94:1269–71. doi: 10.1002/jmv.27521
8. Öztürk C, Yüce Sezen A, Savaş Sen Z, Özdem S. Bilateral acute anterior uveitis and corneal punctate epitheliopathy in children diagnosed with multisystem inﬂammatory syndrome secondary to COVID-19. Ocul Immunol Inﬂamm. (2021) 29:700–4. doi: 10.1080/09273948.2021.1909070
9. Kartık İK, Gulla KM, John J, Satapathy AK, Sahu S, Behera B, et al. COVID-19 related multi-inflammationy syndrome presenting with uveitis - a case report. Indian J Ophthalmol. (2021) 69:1319–21. doi: 10.4103/ijo.IJO_32_21
10. Vergouwen DPC, Rothova A, Berge JCT, Verdijk RM, van Laar JAM, Vingerling JR, et al. Current insights in the pathogenesis of scleritis. Exp Eye Res. (2020) 197:108078. doi: 10.1016/j.exer.2020.108078
11. Gorelik M. Learning about Kawasaki disease from COVID-19 and the multisystem inﬂammatory syndrome in children. Curr Opin Pediatr. (2021) 33:603–9. doi: 10.1097/MOP.0000000000001047
12. Palejwala NV, Yeh S, Angeles-Han ST. Current perspectives on ophthalmic manifestations of childhood rheumatic diseases. Curr Rheumatol Rep. (2013) 15:341. doi: 10.1007/s11926-013-0341-3
13. Suganuma E, Kameb T, Sato S, Hamamoto M, Kawano Y. A case of Kawasaki disease complicated with retinal vasculitis. Pediatr Int. (2019) 61:829–30. doi: 10.1111/ped.13938
14. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientiﬁc statement for health professionals from the American Heart Association. Circulation. (2017) 135:e927–9. doi: 10.1161/CIR.0000000000000484
15. Lim EJ, Aris IM, Choo J, Wong TY, Li LThe association between coronary artery measurements and retinal microvasculature in children with new onset of Kawasaki disease. Sci Rep. (2019) 9:16714. doi: 10.1038/s41598-019-35220-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conﬂict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their afﬁliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Matsubara, Tamura, Kasuya, Mizobe, Hiwada, Seki, Makino and Yamagata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.